ARAV vs. MBIO, BPTS, AGRX, CYCC, NBY, BPTSY, ARDS, ONCO, VRPX, and CYTO
Should you be buying Aravive stock or one of its competitors? The main competitors of Aravive include Mustang Bio (MBIO), Biophytis (BPTS), Agile Therapeutics (AGRX), Cyclacel Pharmaceuticals (CYCC), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Aridis Pharmaceuticals (ARDS), Onconetix (ONCO), Virpax Pharmaceuticals (VRPX), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
Aravive (NASDAQ:ARAV) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
35.8% of Aravive shares are owned by institutional investors. Comparatively, 9.9% of Mustang Bio shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Comparatively, 2.1% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Aravive's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.
Aravive currently has a consensus target price of $13.50, suggesting a potential upside of 33,565.84%. Mustang Bio has a consensus target price of $17.25, suggesting a potential upside of 6,284.16%. Given Aravive's higher probable upside, research analysts clearly believe Aravive is more favorable than Mustang Bio.
Mustang Bio received 64 more outperform votes than Aravive when rated by MarketBeat users. Likewise, 64.12% of users gave Mustang Bio an outperform vote while only 62.28% of users gave Aravive an outperform vote.
Mustang Bio has lower revenue, but higher earnings than Aravive. Mustang Bio is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
Aravive has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Mustang Bio has a net margin of 0.00% compared to Aravive's net margin of -569.65%. Aravive's return on equity of 0.00% beat Mustang Bio's return on equity.
Summary
Aravive beats Mustang Bio on 9 of the 15 factors compared between the two stocks.
Get Aravive News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools